Client News

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update

Abivax provides business and operational update

AdhereTech Appoints Innes Meldrum as President and Chief Executive Officer

Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with the full chemistry support of Enamine

Element Materials unveils fully integrated pharma services platform, strengthening its expanding Life Sciences Division

invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding

Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer

InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)